AccScience Publishing / AIH / Online First / DOI: 10.36922/aih.2973
REVIEW

AI and pharma: Transforming the paradigm, embracing the new era

Harjeevan Singh Kang1*
Show Less
1 College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
AIH 2024, 1(3), 1–9; https://doi.org/10.36922/aih.2973
Submitted: 20 February 2024 | Accepted: 15 March 2024 | Published: 14 May 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

This review delves into the dynamic intersection of artificial intelligence (AI) and the pharmaceutical industry, exploring a wide spectrum of clinical and commercial applications, challenges and risks, potential solutions, and future outlooks as these domains converge. With the rapid advancement of AI, this review addresses the profound implications of AI in the life sciences sector, emphasizing its potential to revolutionize drug discovery, clinical trials, personalized medicine, pharmacovigilance, sales, and marketing. While lauding the paradigm-shifting prospects, this paper confronts the ethical, privacy, and bias risks entwined with AI development and deployment. Forward-looking solutions, including fortified data governance frameworks, transparent AI algorithms, and interdisciplinary alliances, stand as bulwarks against these impediments. Furthermore, it considers the possibilities afforded to AI by emergent technologies, such as quantum cloud computing and low-code solutions. In conclusion, this review envisions a future where AI, in collaboration with innovative technologies, reshapes the pharmaceutical landscape. By promoting informed discussions and collaboration, this review seeks to empower the industry to harness the transformative potential of AI in an ethical manner.

Keywords
Artificial intelligence
Pharma
Clinical
Marketing
Sales
Regulation
Funding
None.
Conflict of interest
There are no conflicts of interest.
References
  1. Toffler A. Future Shock. New York: Bantam Books; 1970.

 

  1. Abed S. A literature review exploring the role of technology in business survival during the Covid-19 lockdowns. Int J Organ Anal. 2022;30(5):1045-1062. doi: 10.1108/IJOA-11-2020-2501

 

  1. Zhu X, Ge S, Wang N. Digital transformation: A systematic literature review. Comput Ind Eng. 2021;162:107774. doi: 10.1016/j.cie.2021.107774

 

  1. Brodeur A, Gray D, Islam A, Bhuiyan S. A literature review of the economics of COVID‐19. J Econ Surv. 2021;35(4):1007-1044. doi: 10.1111/joes.12423

 

  1. Schwab K. The Fourth Industrial Revolution. New York: Portfolio Penguin; 2017.

 

  1. Russell S, Norvig P. Artificial Intelligence: A Modern Approach. 4th ed. London: Pearson; 2022.

 

  1. Selvaraj C, Chandra I, Singh S. Artificial intelligence and machine learning approaches for drug design: Challenges and opportunities for the pharmaceutical industries. Mol Divers. 2021;26:1893-1913. doi: 10.1007/s11030-021-10326-z

 

  1. Kulkov I. The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technol Soc. 2021;66:101629. doi: 10.1016/j.techsoc.2021.101629

 

  1. Bodenheimer T, Sinsky C. From triple to quadruple aim: Care of the patient requires care of the provider. Ann Fam Med. 2014;12(6):573-576. doi: 10.1370/afm.1713

 

  1. Kelly BS, Judge C, Bollard SM, et al. Radiology artificial intelligence: A systematic review and evaluation of methods (RAISE). Eur Radiol. 2022;32(11):7998-8007. doi: 10.1007/s00330-022-08784-6

 

 

  1. Secinaro S, Calandra D, Secinaro A, Muthurangu V, Biancone P. The role of artificial intelligence in healthcare: A structured literature review. BMC Med Inform Decis Mak. 2021;21:125. doi: 10.1186/s12911-021-01488-9

 

  1. Association of the British Pharmaceutical Industry. Code of Practice for the Pharmaceutical Industry 2021; 2021. Available from: https://www.abpi.org.uk/publications/code-of-practice-for-the-pharmaceutical-industry-2021 [Last accessed on 2023 May 01].

 

  1. EY. EY Smart Reviewer; 2023. Available from: https://www. ey.com/en_uk/life-sciences/smart-reviewer [Last accessed on 2023 Jun 15].

 

  1. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: Reporting requirements throughout a product’s lifecycle. Ther Adv Drug Saf. 2022;13:1-16. doi: 10.1177/20420986221125006

 

  1. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products; 2023. Available from: https://www.who.int/publications/i/ item/10665-42493 [Last accessed on 2023 Jun 18].

 

  1. Salas M, Petracek J, Yalamanchili P, et al. The use of artificial intelligence in pharmacovigilance: A systematic review of the literature. Pharmaceut Med. 2022;36(5):295-306. doi: 10.1007/s40290-022-00441-z

 

  1. Association of the British Pharmaceutical Industry. Medicine Lifecycle; 2021. Available from: https://www.abpi.org.uk/ value-and-access/uk-medicine-pricing/medicine-lifecycle [Last accessed on 2023 Jun 24].

 

  1. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93. doi: 10.2174/1872208316666220802151129

 

  1. Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial intelligence applied to clinical trials: Opportunities and challenges. Health Technol (Berl). 2023;13(2):203-213. doi: 10.1007/s12553-023-00738-2

 

  1. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577-591. doi: 10.1016/j.tips.2019.05.005

 

  1. Hockings JK, Pasternak AL, Erwin AL, Mason N, Eng C, Hicks JK. Pharmacogenomics: An evolving clinical tool for precision medicine. Cleve Clin J Med. 2020;87(2):91-99. doi: 10.3949/ccjm.87a.19073

 

  1. CNBC. Google Cloud Launches A.I.-Powered Tools to Accelerate Drug Discovery, Precision Medicine; 2023. Available from: https://www-cnbc-com.cdn.ampproject. org/c/s/www.cnbc.com/amp/2023/05/16/google-cloud-launches-ai-tools-to-accelerate-drug-discovery.html [Last accessed on 2023 Jun 13].

 

  1. Euchner J. Generative AI. Res Manage. 2023;66(3):71-74. doi: 10.1080/08956308.2023.2188861

 

  1. Ebert C, Louridas P. Generative AI for software practitioners. IEEE Softw. 2023;40(4):30-38. doi: 10.1109/MS.2023.3265877

 

  1. McKinsey. The Economic Potential of Generative AI: The Next Productivity Frontier; 2023. Available from: https:// www.mckinsey.com/capabilities/mckinsey-digital/our-insights/the-economic-potential-of-generative-ai-the-next-productivity-frontier [Last accessed on 2023 Jun 15].

 

  1. Forbes. Who’s Winning the Chatbot Race? These Companies -from Meta to Alibaba -Have All Introduced AI-Powered Programs; 2023. Available from: https://www. forbes.com/sites/ariannajohnson/2023/04/13/whos-winning-the-chatbot-race-these-companies--from-meta-to-alibaba-have-all-introduced-ai-powered-programs [Last accessed on 2023 Jun 13].

 

  1. Rosario A, Moniz L, Cruz R. Data science applied to marketing. J Inform Sci Eng. 2021;37(5):1067-1081. doi: 10.6688/JISE.202109_37(5).0006

 

  1. Verma S, Sharma R, Deb S, Maitra D. Artificial intelligence in marketing: Systematic review and future research direction. Int J Inf Manag Data Insights. 2021;1(1):100002. doi: 10.1016/j.jjimei.2020.100002

 

  1. Schoenherr T, Speier‐Pero C. Data science, predictive analytics, and big data in supply chain management: Current state and future potential. J Bus Logist. 2015;36(1):120-132. doi: 10.1111/jbl.12082

 

  1. Huang Y. Situation Awareness and Information Fusion in Sales and Customer Engagement: A Paradigm shift. IEEE Conference on Cognitive and Computational Aspects of Situation Management; 2020. p. 113-121. doi: 10.1109/CogSIMA49017.2020.9215990

 

  1. Singh VL, Manrai AK, Manrai L. Sales training: A state of the art and contemporary review. J Econ Finance Admin Sci. 2015;20(38):54-71. doi: 10.1016/j.jefas.2015.01.001

 

  1. Luo X, Qin M, Fang Z, Qu Z. Artificial intelligence coaches for sales agents: Caveats and solutions. J Mark. 2021;85(2):14-32. doi: 10.1177/0022242920956676

 

  1. Roy M. Artificial intelligence in pharmaceutical sales & marketing-a conceptual overview. Int J Innov Res Technol. 2022;8(11):897-902.

 

  1. Malthouse E, Copulsky J. Artificial intelligence ecosystems for marketing communications. Int J Advert. 2023;42(1):128-140. doi: 10.1080/02650487.2022.2122249

 

  1. Alkaissi H, McFarlane SI. Artificial hallucinations in ChatGPT: Implications in scientific writing. Cureus. 2023;15(2):e35179. doi: 10.7759/cureus.35179

 

  1. Anagnostou M, Karvounidou O, Katritzidaki C, et al. Characteristics and challenges in the industries towards responsible AI: A systematic literature review. Ethics Inf Technol. 2022;24(3):1-18. doi: 10.1007/s10676-022-09634-1

 

  1. Guembe B, Azeta A, Misra S, Osamor V, Fernandez-Sanz L, Pospelova V. The emerging threat of ai-driven cyber attacks: A review. Appl Artif Intell. 2022;36(1):1-34. doi: 10.1080/08839514.2022.2037254

 

  1. McKinsey & Company. Four Ways Pharma Companies can make their Supply Chains More Resilient; 2021. Available from: https://www.mckinsey.com/industries/life-sciences/ our-insights/four-ways-pharma-companies-can-make-their-supply-chains-more-resilient [Last accessed on 2023 Jun 14].

 

  1. Minh D, Wang H, Li Y, Nguyen T. Explainable artificial intelligence: A comprehensive review. Artif Intell Rev. 2022;55:1-66. doi: 10.1007/s10462-021-10088-y

 

  1. Information Commissioner’s Office. Consent; 2018. Available from: https://ico.org.uk/for-organisations/ uk-gdpr-guidance-and-resources/lawful-basis/a-guide-to-lawful-basis/lawful-basis-for-processing/consent [Last accessed on 2023 Jun 17].

 

  1. Bostrom N. Existential risks: Analyzing human extinction scenarios and related hazards. J Evol Technol. 2002;9:1-30.

 

  1. Li J, Huang J. Dimensions of artificial intelligence anxiety based on the integrated fear acquisition theory. Technol Soc. 2020;63:101410. doi: 10.1016/j.techsoc.2020.101410

 

  1. The Independent. Facebook’s Artificial Intelligence Robots Shut Down After they Start Talking to Each other in their Own Language; 2017. Available from: https://www.independent. co.uk/life-style/facebook-artificial-intelligence-ai-chatbot-new-language-research-openai-google-a7869706.html [Last accessed on 2023 Jun 13].

 

  1. The Washington Post. The Google Engineer who Thinks the Company’s AI has Come to Life; 2022. Available from: https:// www.washingtonpost.com/technology/2022/06/11/google-ai-lamda-blake-lemoine [Last accessed on 2023 Jun 13].

 

  1. National Artificial Intelligence Initiative: Overseeing and Implementing the United States National AI Strategy; 2021. Available from: https://www.ai.gov [Last accessed on 2023 Jun 05].

 

  1. US Chamber of Commerce. Artificial Intelligence Commission Report; 2023. Available from: https://www.uschamber.com/ technology/artificial-intelligence-commission-report [Last accessed on 2023 Jun 22].

 

  1. US Chamber of Commerce. State-by-State Artificial Intelligence Legislation Tracker; 2022. Available from: https://www. uschamber.com/technology/state-by-state-artificial-intelligence-legislation-tracker [Last accessed on 2023 Jul 16].

 

  1. The White House. Blueprint for an AI Bill of Rights: Making Automated Systems Work for the American People; 2022. Available from: https://www.whitehouse.gov/ostp/ai-bill-of-rights [Last accessed on 2023 Jun 17].

 

  1. National Institute of Standards and Technology. AI Risk Management Framework; 2023. Available from: https:// www.nist.gov/itl/ai-risk-management-framework [Last accessed on 2032 Jun 23].

 

  1. Financial Times. Europe has Fallen Behind America and the Gap is Growing; 2023. Available from: https://www.ft.com/ content/80ace07f-3acb-40cb-9960-8bb4a44fd8d9 [Last accessed on 2023 Jun 19].

 

  1. UK Government. National AI Strategy; 2021. Available from; https://www.gov.uk/government/publications/national-ai-strategy [Last accessed on 2023 Apr 29].

 

  1. UK Government. UK Unveils World Leading Approach to Innovation in First Artificial Intelligence White Paper to Turbocharge Growth; 2023. Available from: https://www.gov. uk/government/news/uk-unveils-world-leading-approach-to-innovation-in-first-artificial-intelligence-white-paper-to-turbocharge-growth [Last accessed on 2023 Jun 21].

 

  1. Information Commissioner’s Office. Artificial Intelligence; 2022. Available from: https://ico.org.uk/for-organisations/ uk-gdpr-guidance-and-resources/artificial-intelligence [Last accessed on 2023 Jun 13].

 

  1. Roberts H, Babuta A, Morley J, Thomas C, Taddeo M, Floridi L. Artificial intelligence regulation in the United Kingdom: A path to good governance and global leadership? Internet Policy Rev. 2023;12(2):1-31. doi: 10.14763/2023.2.1709

 

  1. European Commission. A European Approach to Artificial Intelligence; 2023. Available from: https://digital-strategy. ec.europa.eu/en/policies/european-approach-artificial-intelligence [Last accessed on 2023 Jun 14].

 

  1. European Parliament. EU AI Act: First Regulation on Artificial Intelligence; 2023. Available from: https://www.europarl. europa.eu/news/en/headlines/society/20230601STO93804/ eu-ai-act-first-regulation-on-artificial-intelligence [Last accessed on 2023 Jun 14].

 

  1. European Parliament. The Artificial Intelligence Act; 2023. Available from: https://artificialintelligenceact.eu [Last accessed on 2023 Jun 14].

 

  1. Financial Times. European Companies Sound Alarm Over Draft AI Law; 2023. Available from: https://www. ft.com/content/9b72a5f4-a6d8-41aa-95b8-c75f0bc92465 [Last accessed on 2023 Jun 30].

 

  1. International Coalition of Medicines Regulatory Authorities. Horizon Scanning Assessment Report - Artificial Intelligence; 2021. Available from: https://www.icmra.info/drupal/sites/ default/files/2021-08/horizon_scanning_report_artificial_ intelligence.pdf [Last accessed on 2023 Jun 21].

 

  1. Center for AI and Digital Policy. G7 and Artificial Intelligence; 2023. Available from: https://www.caidp.org/resources/ g7-japan-2023 [Last accessed on 2023 Jun 22].

 

  1. Global Partnership on Artificial Intelligence. GPAI/The Global Partnership on Artificial Intelligence; 2023. Available from: https://gpai.ai [Last accessed on 2023 Jun 17].

 

  1. Brennan C, Vlaev I, Blakemore M, Smith N. Consumer education and empowerment in Europe: Recent developments in policy and practice. Int J Consum Stud. 2017;41(2):147-157. doi: 10.1111/ijcs.12322.

 

  1. Equality and Human Rights Commission. Protected Characteristics; 2021. Available from: https://www. equalityhumanrights.com/en/equality-act/protected-characteristics [Last accessed on 2023 Jul 05].

 

  1. UK Government Office for Science. Innovation: Managing Risk, not Avoiding; 2014. Available from: https://www.gov. uk/government/publications/innovation-managing-risk-not-avoiding-it [Last accessed on 2023 Jul 16].

 

  1. Association of the British Pharmaceutical Industry. How Skill Requirements are Changing; 2023. Available from: https:// www.abpi.org.uk/publications/how-skill-requirements-are-changing [Last accessed on 2023 Jun 10].

 

  1. Harvard Business Review. Your Company is Too Risk- Averse; 2020. Available from: https://hbr.org/2020/03/your-company-is-too-risk-averse [Last accessed on 2023 Jul 13].

 

  1. Rogers E. Diffusion of Innovations. London: Collier- Macmillan; 1962.

 

  1. Durao F, Carvalho J, Fonseka A, Garcia V. A systematic review on cloud computing. J Supercomput. 2014;68:1321-1346. doi: 10.1007/s11227-014-1089-x

 

  1. Solenov D, Brieler J, Scherrer J. The potential of quantum computing and machine learning to advance clinical research and change the practice of medicine. Mo Med. 2018;115(5):463-467.

 

  1. Soeparno H, Perbangsa A. Cloud quantum computing concept and development: A systematic literature review. Procedia Comput Sci. 2021;179:944-954. doi: 10.1016/j.procs.2021.01.084

 

  1. Tyagi A. Handbook of Research on Quantum Computing for Smart Environments. Hershey: IGI Global; 2023.

 

  1. Binzer B, Winkler T. Democratizing software development: A systematic multivocal literature review and research agenda on citizen development. Int Conf Softw Bus. 2022;463:244-259. doi: 10.1007/978-3-031-20706-8_17

 

  1. CNBC. How Generative A.I. and Low-Code are Speeding up Innovation; 2023. Available from: https://www.cnbc. com/2023/05/19/generative-ai-and-low-code-are-speeding-up-innovation.html [Last accessed on 2023 May 20].

 

  1. World Economic Forum. Here’s how Experts See AI Developing Over the Coming Years; 2023. Available from: https://www. weforum.org/agenda/2023/02/experts-ai-developing-over-the-coming-years [Last accessed on 2023 Jun 08].
Share
Back to top
Artificial Intelligence in Health, Electronic ISSN: 3029-2387 Print ISSN: 3041-0894, Published by AccScience Publishing